NYPOZI
NYPOZI
Approved
DIN Number
02521008
Drug Class
Human
Market Date
Jan 24, 2024
Company
HC
TANVEX BIOPHARMA USA, INC.
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number02521008
AIG Number0123525003
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
,
Prescription
A
ATC Code
L03AA02 FILGRASTIM
Product Specifications
Dosage FormSolution
Route of AdministrationIntravenous
,
Subcutaneous
AHFS Classification20:16.00
Health Canada Classification
ACTIVE INGREDIENTS (1)
FILGRASTIMActive
Strength: 480 MCG / 0.8 ML
Monograph: FILGRASTIM